A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants

NCT05515601
clinicaltrials.gov
Phase
Phase 1
clinicaltrials.gov
Recruitment status
Completed
clinicaltrials.gov
Participants
396
clinicaltrials.gov
Lead sponsor
Eli Lilly and Company
clinicaltrials.gov
Start date
2022-08-31
clinicaltrials.gov
Number of sites
6
clinicaltrials.gov

Summary
The main purpose of this study is to evaluate amount of mirikizumab (test) that gets into the blood stream and how long it takes the body to get rid of it, when given via autoinjector compared to mirikizumab (reference) solution given via autoinjector. The information about any adverse effects experienced will be collected and the tolerability of mirikizumab will also be evaluated. Screening is required within 35 days prior to enrolment. For each participant, the total duration of the clinical trial will be about 17 weeks including screening.
clinicaltrials.gov
Short title
A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants
clinicaltrials.gov
Official title
A Bioequivalence Study of Subcutaneous Injections of Mirikizumab Reference Solution Using an Investigational 1-mL Autoinjector and Mirikizumab Test Solution Formulation Using an Investigational 1-mL Autoinjector in Healthy Participants
clinicaltrials.gov

Registry reports results
Yes
clinicaltrials.gov
Listing at source
Listed
clinicaltrials.gov
Recruitment status
Completed
clinicaltrials.gov
Phase
Phase 1
clinicaltrials.gov
Study type
Interventional
clinicaltrials.gov

Completion date
2023-02-20
clinicaltrials.gov
First posted
2022-08-25
clinicaltrials.gov
Registry last updated
2024-07-05
clinicaltrials.gov
Primary completion date
2023-02-20
clinicaltrials.gov
Start date
2022-08-31
clinicaltrials.gov

Actual participants
396
clinicaltrials.gov
Participants
396
clinicaltrials.gov
Participant count basis
Actual
clinicaltrials.gov
Protocol amendments
2
clinicaltrials.gov
Number of sites
6
clinicaltrials.gov

Data monitoring committee
No
clinicaltrials.gov
Registry sponsor category
Industry
clinicaltrials.gov
Lead sponsor
Eli Lilly and Company
clinicaltrials.gov
Source registry
ClinicalTrials.gov
clinicaltrials.gov

Registry ID
NCT05515601
clinicaltrials.gov
ClinicalTrials.gov ID
NCT05515601
clinicaltrials.gov
Registry record
Open registry record
clinicaltrials.gov

Allocation
Randomised
Model
Parallel groups
Purpose
Basic science
Masking
Single masking
Masked roles
Participants
Sources for study design
clinicaltrials.gov

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab

    Timeframe: Predose on Day 1, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 postdose

    PK: Cmax of mirikizumab was evaluated.

  2. PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Mirikizumab

    Timeframe: Predose on Day 1, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 postdose

    PK: AUC\[0-∞\] of Mirikizumab was evaluated.

  3. PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of Mirikizumab

    Timeframe: Predose on Day 1, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 postdose

    PK: AUC\[0-tlast\] of Mirikizumab was evaluated.

Sources for outcomes
clinicaltrials.gov

Sex
All
Age groups
Adults, Older adults
Minimum age
18 Years
Maximum age
65 Years
Healthy volunteers
Yes

  • Participants who are overtly healthy as determined by medical evaluation
  • Have a body mass index( BMI) within the range of 18.0 to 34.0 kg/m2, inclusive.
  • are males or non-pregnant women of childbearing potential (WOCBP) or women not of childbearing potential (WNOCBP).

  • Have significant allergies to humanized monoclonal antibodies or known allergies to mirikizumab, related compounds or any components of the formulation, or history of significant atopy
  • Have an abnormal blood pressure, pulse rate, or temperature as determined by the investigator
  • Intend to use over-the-counter or prescription medication, including herbal medications and traditional medications, within 7 days prior to dosing
  • Are lactating or pregnant
Sources for eligibility
clinicaltrials.gov

  • Altasciences Clinical Los Angeles, IncCypress, United States
  • LabCorp CRU, Inc.Daytona Beach, United States
  • AxisDilworth, United States
  • QPSSpringfield, United States
  • Labcorp Clinical Research LPDallas, United States
  • LabCorp CRU, Inc.Madison, United States
Sources for sites
clinicaltrials.gov

Other registry identifiers

  • I6T-MC-AMBT
Sources for references
clinicaltrials.gov

Related records

Drugs (1)

Lead sponsors (1)

Targets (2)